The company had posted a net loss after taxes, minority interest and share of profit/loss of associates of Rs 94.11 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a statement.
Consolidated total income from operations of the company also rose to Rs 1,463.05 crore for the quarter under consideration as against Rs 1,371.10 crore for the same period a year ago.
Commenting on the results, Jubilant Life Sciences Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said: "Our performance in this quarter is a continuation of the good growth momentum of the last two quarters, with better earnings across both segments."
The company's pharmaceuticals segment witnessed sustained improvement due to increase in revenues across all geographies led by growth in North America. Margins in our Life Science ingredients business were better, led by specialty intermediates and nutritional products, they added.
Also Read
During the quarter international revenues stood at Rs 1,054 crore, contributing 72 per cent to the overall mix, Jubilant Life Sciences said.
In FY 2016, the growth is expected to be driven by pharmaceuticals segment primarily led by growth in North America in the specialty pharmaceuticals business, Jubilant Life Sciences said.
The Life Science ingredients segment is expected to deliver better margins compared to FY 2015 led by improved operational efficiency and growth in specialty intermediates and nutritional products, it added.
Shares of Jubilant Life Sciences today closed at Rs 401.60 per scrip on BSE, down 1.52 per cent from it's previous close.